As of November 10, 2026, Structure Therapeutics Inc. is a publicly traded company (Nasdaq: GPCR); its largest reported holder is Fidelity (FMR), with 15% on Schedule 13G/A of November 5, 2026, then Wellington Management (10.1%). The largest insider holding is Jun Yoon, the chief financial officer, with 2,956,242 shares (1.4% of shares outstanding), per Form 4 of March 23, 2026 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Structure Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Structure Therapeutics Inc. a real, registered company?
- Structure Therapeutics Inc. files with the SEC under CIK 1888886 (its SEC filings).
- Its shares are listed under the ticker GPCR on Nasdaq (SEC company record).
- Incorporated in E9; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under STRUCTURE THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Matthew Lang, Chief Operating Officer (Form 8-K filed 2026-04-15). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Structure Therapeutics Inc.'s owners and officers?
Structure Therapeutics Inc.: business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 15% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 13.2% |
| Schedule 13G/A, 2026-02-17 | Bvf Partners L P/Il | 4.9% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 5.95% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 10.1% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 15% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 7.7% |
| Schedule 13G, 2025-11-14 | Avoro Capital Advisors LLC | 9.38% |
| Schedule 13G/A, 2025-11-14 | Deep Track Capital, LP | 7.32% |
| Schedule 13G/A, 2025-11-07 | Wellington Management Group LLP | 11.9% |
| Schedule 13G/A, 2025-11-07 | Wellington Management Group LLP | 9.9% |
| Schedule 13G, 2025-08-18 | Bvf Partners L P/Il | 5.6% |
Questions about who owns Structure Therapeutics Inc.
Who owns Structure Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Structure Therapeutics Inc.: Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05), Wellington Management Group LLP (10.1%, Schedule 13G/A, filed 2026-02-10), Avoro Capital Advisors LLC (9.38%, Schedule 13G, filed 2025-11-14), Janus Henderson Group PLC (7.7%, Schedule 13G/A, filed 2025-11-14) and Deep Track Capital, LP (5.95%, Schedule 13G/A, filed 2026-02-13).
Who are the largest shareholders of Structure Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Structure Therapeutics Inc. on this page are Fmr LLC (15%), Wellington Management Group LLP (10.1%) and Avoro Capital Advisors LLC (9.38%).
When did Fmr LLC buy into Structure Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-02-05, reporting 15%; its latest, Schedule 13G/A filed 2026-11-05, reports 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Structure Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Structure Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Structure Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-15 | Matthew Lang | Chief Operating Officer | appointed | 2026-04-15 |
Which insiders own Structure Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief financial officer: 2,956,242 shares (1.4% of shares outstanding), 1,401,656 held directly and 1,554,586 indirectly (Form 4, 2026-03-23).
- , the chief executive and a director: 2,956,179 shares (1.4% of shares outstanding), 1,401,593 held directly and 1,554,586 indirectly (Form 4, 2026-03-23).
- Fidelity (FMR), a 10% owner: 261,777 shares (0.12% of shares outstanding), held indirectly through F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 1 other F-Prime Capital fund (Form 4, 2026-07-24).
- , the chief medical officer: 258,228 shares (0.12% of shares outstanding) (Form 4, 2026-09-22).
- , the chief scientific officer: 228,960 shares (0.11% of shares outstanding) (Form 4, 2026-09-02).
Shares outstanding: 214,771,065 as of 2026-10-31, from the company's latest SEC cover page.
How much has Structure Therapeutics Inc. raised?
No fundraising or offering filing from Structure Therapeutics Inc. is on file with us.
Keep reading
More on Structure Therapeutics Inc. and the records around it.
Structure Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Apr 2026
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/structure-therapeutics